港股異動丨中康控股飆升近38%,創逾1個月新高
DeepSeek概念股中康控股(2361.HK)盤中漲幅進一步擴大,一度飆升近38%,報4.6港元,股價創1月9日以來新高。2月6日,中康控股旗下主要業務平臺中康科技成功接入“DeepSeek大模型”,並與自主研發的“卓睦鳥醫療大模型”融合,助力AI醫療加速落地。分析人士指出,DeepSeek大模型的加入,爲中康科技在健康醫療的注入更強大的智能技術,與中康科技“卓睦鳥醫療大模型”在垂直醫療場景深度融合,共同突破複雜醫學推理、多源數據融合等技術瓶頸,進一步提升其在醫療數據分析、輔助決策、健康管理等場景中的應用效果,推動AI醫療服務的精準化與普惠化。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.